Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$73.71 USD

73.71
3,674,571

+0.41 (0.56%)

Updated Jul 18, 2024 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ritujay Ghosh headshot

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

by Ritujay Ghosh

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Q2 Earnings Release?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

by Ritujay Ghosh

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

The Zacks Analyst Blog Highlights: Google, NVIDIA, Costco, Gilead Sciences and Morgan Stanley

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Google, NVIDIA, Costco, Gilead Sciences and Morgan Stanley

Sheraz Mian headshot

Top Research Reports for Alphabet, NVIDIA & Costco

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), NVIDIA (NVDA) and Costco Wholesale (COST).

Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.

Ritujay Ghosh headshot

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

by Ritujay Ghosh

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.

Gilead Sciences (GILD) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -23.97% and -1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.

Lilly (LLY) Q2 Earnings Top Estimates, Sales Lag, Stock Down

by Zacks Equity Research

Eli Lilly (LLY) reports mixed Q2 results. Total revenues in the quarter hurt by the coronavirus pandemic

Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Kinjel Shah headshot

Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More

by Kinjel Shah

Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.

    Ritujay Ghosh headshot

    Coronavirus Vaccine Development Puts These Stocks in Focus

    by Ritujay Ghosh

    Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.

    Sweta Killa headshot

    What Lies Ahead for Healthcare ETFs in Q2 Earnings?

    by Sweta Killa

    The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.

    How Hard Will Coronavirus Hit Lilly's (LLY) Q2 Earnings?

    by Zacks Equity Research

    Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports second-quarter earnings.

    David Borun headshot

    Markets Remain Calm But More Data and Earnings are Coming

    by David Borun

    Equities trend sideways as we wait for Congress and 30% of the S&P is set to report results.

    Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings?

    by Zacks Equity Research

    Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.

    Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More

    by Zacks Equity Research

    The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

    Earnings Preview: Gilead Sciences (GILD) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Roche's (RHHBY) 1H20 Sales Hit by the Coronavirus Pandemic

    by Zacks Equity Research

    Roche's (RHHBY) performance in first-half 2020 was unimpressive as it bears the brunt of the COVID-19 outbreak.

    Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker

    by Zacks Equity Research

    Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.

    Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed the most recent trading day at $78.08, moving +0.74% from the previous trading session.

    Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation

    by Zacks Equity Research

    Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.